Trial Profile

Relative Bioavailability of a Single 200 MG Dose Of Cenobamate (YKP3089) Given As An Oral Tablet Or As An Oral Suspension And The Effect Of Food On A Single 200 MG Dose Of Cenobamate Given As An Oral Suspension

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cenobamate (Primary) ; Cenobamate (Primary)
Indications Anxiety disorders; Bipolar disorders; Neuropathic pain; Partial epilepsies; Tonic-clonic epilepsy
Focus Pharmacokinetics
Sponsors SK Life Science

21 Nov 2025 According to SK Life Science media release, new data from this study will be presented at the 2025 American Epilepsy Society (AES) Annual Meeting in Atlanta, Georgia, December 5-9, 2025.
06 Oct 2021 Status changed from active, no longer recruiting to completed.
10 Mar 2021 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com